SciNeuro Pharmaceuticals
PrivateLast Round
Series B
Dec 4, 2025
Total Funding Raised
$153M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
SciNeuro Pharmaceuticals operates in Healthcare & Life Sciences and is based in Rockville, Maryland. Its latest recorded funding round was a Series B round in December 2025.
SciNeuro Pharmaceuticals is a biotechnology company that develops innovative drugs and therapies for the treatment of central nervous system and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SciNeuro Pharmaceuticals Comparables
Compare SciNeuro Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neuron23 | 83% | |
| Korsana Biosciences | 82% | |
| Alector | 76% |
For institutional investors. Book with your work email.
SciNeuro Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 4, 2025 | ||||
| VC Round | Dec 4, 2025 | ||||
| Series A | Dec 8, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
SciNeuro Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boyu Capital | Series A |
| Zoo Capital | Series A |
| TF Capital | Series A |
| ARCH Venture Partners | VC Round, Series B, Series A |
| Sequoia Capital | Series A |
| The Michael J. Fox Foundation for Parkinson's Research | VC Round, Series B |
| Lilly Asia Ventures | VC Round, Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors grew 133% MoM, reaching 5.8K.
- Jan 12, 2026
Developing a new de novo amyloid beta antibody program in collaboration with Novartis.
For institutional investors. Book with your work email.
SciNeuro Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SciNeuro Pharmaceuticals's valuation, stock price, and market status.
Is SciNeuro Pharmaceuticals a public or private company?
SciNeuro Pharmaceuticals is a private company.
What is the current stock price of SciNeuro Pharmaceuticals?
SciNeuro Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks SciNeuro Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SciNeuro Pharmaceuticals worth (valuation)?
Valuation information for SciNeuro Pharmaceuticals is not publicly available.
Can I buy SciNeuro Pharmaceuticals stock?
SciNeuro Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SciNeuro Pharmaceuticals's last funding round?
SciNeuro Pharmaceuticals's most recent funding round was Series B on December 4, 2025.
Who are the main investors in SciNeuro Pharmaceuticals?
Key investors in SciNeuro Pharmaceuticals include ARCH Venture Partners, Lilly Asia Ventures, Lilly Asia Ventures.
Will SciNeuro Pharmaceuticals IPO soon?
No public IPO plans have been announced for SciNeuro Pharmaceuticals.
How can I track SciNeuro Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in SciNeuro Pharmaceuticals's shares on secondary markets.